Silo Pharma Advances AI Through AMD Program
SARASOTA, Fla., July 14, 2026 Silo Pharma announced that its wholly owned subsidiary, QwikAgents, has been accepted into AMD’s...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SARASOTA, Fla., July 14, 2026 Silo Pharma announced that its wholly owned subsidiary, QwikAgents, has been accepted into AMD’s...
SANTA CLARA, Calif. and PUNE, India , May 7, 2026 Persistent Systems announced it has achieved the Databricks Brickbuilder...
Pune, India – May 5, 2026 Persistent Systems has partnered with the Indian Institute of Technology (IIT) Kharagpur to...
